Additionally, recent clinical investigations revealed that targeting sialidase-1 (neuraminidase-1, Neu-1) by reducing total sialic acid contents may represent a possible therapeutic strategy in CAD therapy [118]. Here, NEU1 is linked to coronary artery disorder.